The Discount That Starves the Pharmacy That Fills It

Medicare's new authority to negotiate lower prices on a set of widely used brand-name drugs took effect this year, and the political framing has been straightforward: seniors pay less for their medications. What that framing leaves out is who is currently absorbing the difference between the old price and the new one, and a recent industry survey suggests the answer is the specialized pharmacies that supply nursing homes, many of which are now warning they may not survive the transition intact.

These are not retail pharmacies with a storefront. Long-term care, or "closed-door," pharmacies exist specifically to package, deliver, and manage medications for nursing home and assisted living residents, a population with more prescriptions, more complex regimens, and less ability to simply switch providers if their pharmacy stops serving their facility. According to a survey representing close to a fifth of the roughly 1,400 such pharmacies nationwide, more than four in five said they expect to reduce services or stop serving certain facilities or regions entirely.

A Price Cut With a Bill Attached to Someone Else

The scale of who is exposed is what makes this more than an industry complaint. Respondents to the survey collectively serve more than 800,000 long-term care patients, close to 40 percent of all nursing home residents nationally, with roughly 300,000 of them in rural communities where a backup pharmacy option may not exist within a reasonable distance. Extrapolated across the sector, the survey's authors estimate that more than 80 percent of nursing home residents, over 1.6 million people, are served by a pharmacy now reporting financial strain severe enough to threaten its ability to keep operating as it does today.

The Mechanics of a Reimbursement Model Built on a Now-Removed Cushion

Long-term care pharmacies typically generate about three-quarters of their revenue through Medicare Part D reimbursement, and that revenue model has long depended on brand-name drug margins to offset chronically thin reimbursement on generics, which make up the bulk of what these pharmacies actually dispense day to day. The newly negotiated Medicare prices apply directly to a set of brand-name drugs that are heavily prescribed in nursing home settings, drugs used for conditions like diabetes, blood clots, and heart failure that are extremely common among long-term care residents. Cutting the brand-name margin without adjusting the underlying generic reimbursement doesn't just shrink profit, it removes the cross-subsidy the entire dispensing model was quietly built on. The pharmacy still has to buy the drug, package it into the specialized single-dose systems nursing homes require, and deliver it on a tight schedule, but the margin that used to make that operationally expensive service financially viable is gone.

Layoffs Now, Access Questions Later

The response already showing up in the data isn't hypothetical. Nearly four in five surveyed pharmacies report they are already laying off staff, the pharmacists, technicians, and delivery personnel who make same-day and next-day dispensing to a nursing home possible in the first place. Losing that staffing capacity is itself a slower-moving version of the same problem the pharmacies are describing: even a pharmacy that stays technically open can become slower, less responsive, and less able to catch the medication errors that a well-staffed closed-door pharmacy is specifically designed to prevent. A bill introduced in both chambers of Congress would create a temporary supply fee for negotiated-price drugs dispensed through long-term care pharmacies specifically, an acknowledgment from lawmakers that the current reimbursement structure wasn't built to absorb this kind of price change without a bridge.

Reading Past the Headline Savings

None of this means the negotiated price program is a mistake, and none of it will show up in a senior's own drug price the way a benefit cut would. A lower negotiated price for a drug and a stable supply chain for delivering that drug to the person who needs it are two separate achievements, and this year's policy solved for the first one without a plan for the second. For families with a parent or spouse in long-term care, the practical takeaway is to ask a facility's pharmacy provider directly, now, whether it is one of the many reporting plans to scale back, rather than discovering the answer the week a delivery doesn't arrive on schedule. The savings are real. So is the strain on the system quietly built to deliver them.

— John Stone